Make that 2 prospective blockbuster approvals in 1 day for Novartis as FDA OKs targeted cancer therapy
May 24 is going to go down as a big day in Novartis’ 2019 highlight reel.
Not only did the FDA stamp an OK on the prospective gene therapy blockbuster Zolgensma, with a record-setting $2.1 million price tag, regulators also green-lighted alpelisib, one of their other top blockbuster candidates of the year.
These are 2 of the slate of 4 blockbusters the pharma giant $NVS highlighted for a commercial rollout this year. And it’s the third big approval this year, behind the MS drug Mayzent, making 2019 a watershed year for the company and new CEO Vas Narasimhan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.